VolitionRX Ltd
Research VolitionRX Ltd (VNRX) on Bullrun: market cap USD 3.01M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerVNRX
- ExchangeNYSE MKT
- CountryUnited States
- SectorHealthcare
- IndustryMedical Devices
- CurrencyUSD
- Market capUSD 3.01M
- Financial periodQ1 2026
- RevenueUSD 985.08K
- Net income-USD 6.66M
- Free cash flow-USD 20.76M
Valuation Snapshot
latest market cap is USD 3.01M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 1.73M | -USD 23.36M | -USD 19.77M | n/a | -4.57 | USD 1.12M | USD 6.71M | -USD 34.25M |
| FY2024 | USD 1.23M | -USD 26.97M | -USD 26.17M | n/a | -0.31 | USD 3.26M | USD 4.81M | -USD 24.91M |
| FY2023 | USD 775.30K | -USD 35.68M | -USD 19.15M | n/a | -0.5 | USD 20.73M | USD 4.83M | -USD 7.80M |
| FY2022 | USD 306.39K | -USD 30.60M | -USD 16.85M | n/a | n/a | USD 10.87M | USD 3.85M | -USD 2.57M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 3.01M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 32.70M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 57.66M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 56.65M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 139.78M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 168.84M | n/a | n/a | n/a |
About VolitionRX Ltd
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is VolitionRX Ltd's market cap?
VolitionRX Ltd's market capitalization is USD 3.01M.
What does VolitionRX Ltd do?
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes.